Stock Picking Algorithm

The Fundamental Package includes our algorithmic forecasts for stocks screened by fundamental criteria. Our algorithms help you find best opportunities for both long and short positions for the stocks within each fundamental screen. The stocks are selected according to five basic valuation categories:

• P/E (price to earnings ratio)
• PEG (price/earnings to growth ratio)
• price-to-book ratio
• price-to-sales ratio

Package Name: Fundamental – High P/E Stocks
Recommended Positions: Long & Short
Forecast Length: 14 Days (04/07/2019 – 04/22/2019)
I Know First Average: 3.84% (Long) & 4.30% (Short)

During the 14 Days forecast, the algorithm had predicted high returns for those seeking stock advice. The best performance in the short position came from ENTA which registered a return of 10.91%. For the long positions the largest growth was registered by BOOM with a return of 9.50%, during the same period. The package itself, had an overall average return of 3.84%, in the long position, providing a premium of 3.31% over the SP500’s return of 0.53%. With regards to the short position, the package had an overall average return of 4.30%, providing investors with a premium of 3.77% over S&P500’s return of 0.53%. The I Know First’s Stock Market Algorithm accurately forecasted 9 out of 10 stocks, for the long position, and 8 out of 10 stocks, for the short position for this 14 Days forecasted period.

Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305 and EDP-938.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

How to interpret this diagram:

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.